Gisslinger, Bettina

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., et al. (2013) · New England Journal of Medicine

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 2,003

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Greiner, G., Sprinzl, B., Górska, A., Ratzinger, F., Gurbisz, M., Witzeneder, N., Schmetterer, K. G., Gisslinger, B., Uyanik, G., Hadzijusufovic, E., et al. (2021) · Blood

Mast cells and histamineGastrointestinal Tumor Research and Treatment

Cited by 189

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Porpaczy, E., Tripolt, S., Hoelbl-Kovacic, A., Gisslinger, B., Bago-Horvath, Z., Casanova-Hevia, E., Clappier, E., Decker, T., Fajmann, S., Fux, D. A., et al. (2018) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentLymphoma Diagnosis and Treatment

Cited by 151

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies

Puda, A., Milosevic, J. D., Berg, T., Klampfl, T., Harutyunyan, A. S., Gisslinger, B., Rumi, E., Pietra, D., Malcovati, L., Elena, C., et al. (2012) · American Journal of Hematology

Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia Treatments

Cited by 105

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status

Kubesova, B., Pavlova, S., Malcikova, J., Kabathova, J., Radova, L., Tom, N., Tichy, B., Plevova, K., Kantorova, B., Fiedorova, K., et al. (2018) · Leukemia

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 82